RSV604 R enantiomer is primarily investigated for its antiviral properties, particularly against respiratory syncytial virus (RSV). It functions as a potent inhibitor of viral replication, targeting the RSV nucleoprotein, which is essential for the virus's life cycle. This compound has shown promise in preclinical studies for reducing viral load and improving clinical outcomes in RSV-infected models. Its potential application lies in the development of therapeutic treatments for RSV infections, especially in high-risk populations such as infants, elderly individuals, and immunocompromised patients. Additionally, it is being explored for use in combination therapies to enhance efficacy and reduce the likelihood of resistance development. Ongoing research aims to optimize its pharmacokinetic properties and evaluate its safety and effectiveness in clinical trials.